This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Analysts' Actions: BBBY DAN JCI KORS X

Xylem was upgraded at DA Davidson to neutral from underperform. $34 price target. Company boosted its guidance and announced surprise growth, DA Davidson said.

Stock Comments/EPS Changes

Acadia Healthcare (ACHC) numbers, price target were raised at Jefferies. Shares are now seen reaching $47. Strong top-line growth and upside in margin expansion, Jefferies said. Estimates lifted into next year. Buy rating.

Actavis (ACT) estimates, price target were increased at Jefferies. Company expects double-digit organic growth after in-line third-quarter results. $168 price target and hold rating.

Archer-Daniels-Midland (ADM) numbers were increased at BMO Capital. Estimates were boosted through 2014. Company is seeing higher divisional profits and a higher LIFO benefit, BMO Capital said. Market perform rating and new $42 price target.

Aetna (AET) estimates, price target were lowered at BMO Capital. Estimates were cut through 2014. Company reduced its guidance, BMO Capital said. Outperform rating and new $70 price target.

Ameriprise (AMP) estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $100. Estimates were also increased, given better asset management growth, Credit Suisse said. Neutral rating.

Cummins (CMI) estimates, price target were reduced at BMO Capital. Shares are now seen reaching $144. Estimates were also cut, given the company's new guidance, BMO Capital said. Outperform rating.

Dana estimates, price target are lowered at Jefferies. Weakness in commercial vehicles, Jefferies said. $23 price target and buy rating.

Gilead (GILD) estimates, price target were increased at Credit Suisse. Estimates were raised through 2015. Company is seeing higher sales and keeping a tight lid on costs, Credit Suisse said. Outperform rating and new $80 price target.

Gilead Sciences (GILD) price target was raised at J.P. Morgan to $85. Strong third-quarter with upside in HIV-related sales, J.P. Morgan said. Overweight rating.

L-3 Communications (LLL) estimates, price target were raised at Credit Suisse. Price target was increased to $97. Estimates were also increased, as the company is realizing higher margins.

LinkedIn (LNKD) estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $288. Estimates were also increased, given the company's new guidance. Outperform rating.

Questcor Pharmaceuticals (QCOR) estimates, price target were increased at Jefferies. QCOR raised its numbers, said Jefferies. Very robust Acthar growth in rheumatology, Jefferies also said. $76 price target and buy rating.

Titan International (TWI) estimates, price target were lowered at Jefferies. TWI decreased its numbers into next year. Uncertainty reflecting commodity end markets and company execution, Jefferies said. $16 price target and Hold rating.

Valero (VLO) estimates, price target were raised at Credit Suisse. Shares are now seen reaching $40. Crude spreads have widened, Credit Suisse said. Neutral rating.

Vertex (VRTX) estimates, price target were cut at Credit Suisse. Shares are now seen reaching $78. Estimates were also reduced, given lower Incivek sales, Credit Suisse said. Neutral rating.

Western Union (WU) numbers were cut at Sterne Agee. Shares are now seen reaching $20. Estimates were also reduced, given the company's new guidance, Sterne Agee said. Buy rating.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Stock quotes in this article: BBBY, DAN, JCI, KORS, X 
This article was written by a staff member of TheStreet.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs